Jones Financial Companies Lllp Increases Holdings in Novo Nordisk A/S $NVO

Jones Financial Companies Lllp boosted its position in Novo Nordisk A/S (NYSE:NVO) by 10.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 149,885 shares of the company’s stock after buying an additional 14,017 shares during the period. Jones Financial Companies Lllp’s holdings in Novo Nordisk A/S were worth $8,335,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Jennison Associates LLC boosted its holdings in Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after purchasing an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P lifted its holdings in shares of Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after buying an additional 187,789 shares during the period. Folketrygdfondet boosted its stake in shares of Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after buying an additional 117,370 shares during the last quarter. Sustainable Growth Advisers LP grew its holdings in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after acquiring an additional 649,390 shares during the period. Finally, State Street Corp raised its position in Novo Nordisk A/S by 0.8% during the second quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after acquiring an additional 47,430 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a 2026 share‑repurchase programme (up to DKK 15bn overall; new tranche up to DKK 3.8bn) — supports capital returns and can cushion share price pressure. Novo Nordisk initiates 2026 share repurchase programme
• Neutral Sentiment: Q4 results beat estimates on revenue and EPS, showing continued obesity‑care strength — but management’s outlook (2026 sales/profit decline) is what tilted sentiment negative. NVO Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Company disclosures: annual report/SEC 20‑F filing and reported insider trading by board/executives — useful for governance context but not the primary driver of the selloff. Novo Nordisk files annual report with the SEC
• Negative Sentiment: Management warned of “painful” U.S. price cuts and issued a weak 2026 guidance range (sales and operating profit expected to fall), which triggered the earlier large drop and remains the main reason investors are selling. Novo Nordisk’s shock 2026 guidance points to obesity battle heating up
• Negative Sentiment: Hims & Hers began offering a compounded Wegovy pill at ~$49 and Novo threatened legal action — the move stokes fears about durable pricing pressure, compounding competition and margin erosion. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
• Negative Sentiment: Market competition and execution gaps: Eli Lilly’s stronger guidance and manufacturing scale are shifting investor preference away from Novo, amplifying downside risk for NVO. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Negative Sentiment: Sales pressure in China: Novo reported its first Ozempic sales decline in the greater China region, which signals geographic headwinds beyond the U.S. pricing story. Novo reports first Ozempic sales drop in greater China region

Novo Nordisk A/S Stock Down 8.2%

NVO opened at $43.32 on Friday. The company has a market cap of $193.40 billion, a PE ratio of 12.48 and a beta of 0.67. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The company has a 50-day moving average price of $53.64 and a 200 day moving average price of $54.06. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 72.86% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Citigroup started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $56.07.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.